健康之路(02587.HK) 8月8日晚间发布公告，根据董事会对本集团截至 2025 年 6 月 30 日止六个月的未 经审核综合管理账目的初步审阅及董事会目前可得资料，本集团预计将于截至 2025 年 6 月 30 日止六个 月录得不少于人民币 600 万元的溢利，而截至 2024 年 6 月 30 日止六个月则录得约人民币 5728 万元的 亏损， 二、价值医疗服务收入减少，主要由于本公司药品批发业务的若干销售代理协议于 2025 年届满，而本 公司正就新销售代理协议进行磋商，以及由于本公司主动调整服务结构及分类，健康医疗综合服务包的 收入减少； 三、数字营销服务收入减少，主要由于经济下滑，导致部分客户选择减少广告及营销开支。 有关本集团截至2025年6月30日止六个月之财务资料的详情，将于本公司截2025年 6 月 30 日止六个月之 中期业绩公告中披露，该公告预计于2025年8月下旬刊发。 据了解，健康之路股份有限公司是国经营数字健康医疗服务平台。 尽管出现上述增长，本集团预计截至 2025 年 6 月 30 日止六个月的收入与 2024 年同期相比将录得约 15% 至 18% 的减少，而截至 202 ...

Company Overview - Health Road Holdings Limited operates a digital health service platform in China and is the fourth largest digital health service platform by registered personal users as of December 31, 2023 [2] - The company is also the fifth largest digital health service platform by revenue for the year 2023 [2] - Since 2001, the company has provided health services to individual users on its digital platform and expanded to offer enterprise services and digital marketing since 2015 [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 1.201 billion yuan, a year-on-year decrease of 3.51% [1] - The net profit attributable to shareholders was -268 million yuan, an increase of 13.42% year-on-year [1] - The gross profit margin stood at 30.47%, with a debt-to-asset ratio of 59.82% [1] Market Performance - As of July 14, the stock price of Health Road was 8.77 HKD per share, reflecting a 13.6% increase with a trading volume of 216 million shares and a turnover of 1.831 billion HKD [1] - Over the past month, the stock has experienced a cumulative decline of 86.59%, and a year-to-date decline of 40.98%, underperforming the Hang Seng Index by 20.34% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.89 times, with a median of 1.17 times [1] - Health Road's P/E ratio is -23.37 times, ranking 68th in the industry [1] - Other companies in the industry have P/E ratios such as Giant Star Medical Holdings at 0.28 times, Jingjiu Health at 0.38 times, and others ranging from 1.96 to 5.45 times [1] Analyst Ratings - Liao Asset Management has given a "Buy" rating for Health Road, with a target price of 68.5 HKD [1]